Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
SunTrust Robinson Humphrey Downgrades Summit Therapeutics plc (SMMT) to Hold
June 27, 2018 1:51 PM EDTSunTrust Robinson Humphrey downgraded Summit Therapeutics plc (NASDAQ: SMMT) from Buy to Hold with a price target of $4.00 (from $22.00) after the company announced that the Phase II PhaseOut DMD study did not meet the pre-specified primary endpoint.
Ridinilazole, now the company's lead... More
Summit Therapeutics (SMMT) to Resumes Trading at 7:30 am ET
June 27, 2018 7:11 AM EDTSummit Therapeutics (NASDAQ: SMMT) to Resumes Trading at 7:30 am ET
... More